Neurocrine Biosciences reported a 41% year-over-year revenue increase to $1.123 billion in Q3 2026, fueled by strong sales of INGREZZA and rapid growth of CRENESSITY and VYKAT XR. The company is diversifying its product portfolio, reducing reliance on INGREZZA, and trades at a forward P/E of 14.19x, lower than sector peers. Upcoming clinical trial results in 2027 for new drugs osavampator and direclidine may further boost growth prospects. This positions Neurocrine as an attractive investment with robust profitability and potential for future expansion.
As of Nov 04, 2026 22:22 WIB, Neurocrine Biosciences (NBIX) trades at USD 164.01 on Pluang, showing a slight 0.51% decline in one day. The stock has a market capitalization of $16.76 billion and an enterprise value of $16.77 billion. Despite the recent minor dip, the typical hold time on Pluang is 26 days, indicating steady investor interest.
Neurocrine Biosciences is reaffirmed as a Buy with a new fair value of $195.80, representing a 19% increase from the recent price. The upgrade is driven by the company's strong Q3 results, with key drugs INGREZZA and CRENESSITY outperforming expectat...
Neurocrine Biosciences reported a 41% year-over-year revenue increase to $1.1 billion in Q3 2026, driven by strong sales of INGREZZA, CRENESSITY, and VYKAT XR. INGREZZA sales grew 17% to $801 million, prompting an upward revision of full-year 2026 gu...
